Bristol Myers Squibb Company $BMY Shares Sold by Stonehage Fleming Financial Services Holdings Ltd

Stonehage Fleming Financial Services Holdings Ltd lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 42.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,000 shares of the biopharmaceutical company’s stock after selling 3,658 shares during the period. Stonehage Fleming Financial Services Holdings Ltd’s holdings in Bristol Myers Squibb were worth $231,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Bristol Myers Squibb by 18.8% in the first quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock worth $2,420,000 after buying an additional 6,267 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Bristol Myers Squibb by 1.4% in the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company’s stock worth $3,967,000 after buying an additional 869 shares during the last quarter. Focus Financial Network Inc. increased its stake in shares of Bristol Myers Squibb by 6.5% in the first quarter. Focus Financial Network Inc. now owns 4,068 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 248 shares during the last quarter. Finally, Everhart Financial Group Inc. increased its stake in shares of Bristol Myers Squibb by 21.0% in the first quarter. Everhart Financial Group Inc. now owns 9,156 shares of the biopharmaceutical company’s stock worth $558,000 after buying an additional 1,591 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup lowered their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $57.14.

Bristol Myers Squibb Stock Down 1.5%

Bristol Myers Squibb stock opened at $44.01 on Friday. The company has a 50-day simple moving average of $46.26 and a 200-day simple moving average of $48.03. The firm has a market capitalization of $89.57 billion, a P/E ratio of 17.74, a P/E/G ratio of 2.25 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.6%. Bristol Myers Squibb’s dividend payout ratio is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.